Literature DB >> 16247325

The severity of cholestatic injury is modulated by the genetic background.

Samuel M Alaish1, Manuel Torres, Marcella Ferlito, Chen-Chih Sun, Antonio De Maio.   

Abstract

Common bile duct ligation (CBDL) compromises the hepatic reticuloendothelial system by impairing the clearing of endotoxin and triggering an overwhelming inflammatory response. The response to endotoxin at the level of cytokine release and subsequent mortality depends on the genetic background in experimental mouse models. We hypothesized that the genetic make-up modulates the inflammatory responses after CBDL. The CBD was ligated in male A/J and B6 mice (8 weeks old). At 7 days post-CBDL, the presence of ascites was observed in 80% of B6 mice but in none of the A/J mice (P < 0.001). B6 mice showed higher mortality than A/J mice (P < 0.05). Both strains had marked cholestatic injury documented histologically. Liver chemistries were markedly elevated in both strains after injury. Plasma levels of the anti-inflammatory cytokine IL-10 were significantly higher in A/J than B6 mice at the 4- and 12-h time points (P < 0.05), whereas proinflammatory cytokine TNF-alpha levels were significantly higher in B6 than A/J mice at 2 h (P < 0.05). Both strains displayed activation of NF-kappaB after CBDL. In conclusion, the contrasting response observed after CBDL between A/J and B6 mice is largely attributable to genetic differences. Survival after CBDL was correlated with an increase in anti-inflammatory cytokines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16247325     DOI: 10.1097/01.shk.0000183392.83272.97

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  7 in total

1.  Cyclopamine attenuates acute warm ischemia reperfusion injury in cholestatic rat liver: hope for marginal livers.

Authors:  Akshay Pratap; Ravikiran Panakanti; Ningning Yang; Ramasubramanian Lakshmi; Kian A Modanlou; James D Eason; Ram I Mahato
Journal:  Mol Pharm       Date:  2011-05-06       Impact factor: 4.939

2.  Gut microbiota, tight junction protein expression, intestinal resistance, bacterial translocation and mortality following cholestasis depend on the genetic background of the host.

Authors:  Samuel M Alaish; Alexis D Smith; Jennifer Timmons; Jose Greenspon; Daniel Eyvazzadeh; Ebony Murphy; Terez Shea-Donahue; Shana Cirimotich; Emmanuel Mongodin; Aiping Zhao; Alessio Fasano; James P Nataro; Alan Cross
Journal:  Gut Microbes       Date:  2013-04-15

3.  The traditional ayurvedic medicine, Eugenia jambolana (Jamun fruit), decreases liver inflammation, injury and fibrosis during cholestasis.

Authors:  Ajay C Donepudi; Lauren M Aleksunes; Maureen V Driscoll; Navindra P Seeram; Angela L Slitt
Journal:  Liver Int       Date:  2011-12-30       Impact factor: 5.828

4.  ENaC activity in collecting ducts modulates NCC in cirrhotic mice.

Authors:  David Mordasini; Dominique Loffing-Cueni; Johannes Loffing; Rohrbach Beatrice; Marc P Maillard; Edith Hummler; Michel Burnier; Geneviève Escher; Bruno Vogt
Journal:  Pflugers Arch       Date:  2015-06-10       Impact factor: 3.657

5.  Epigallocatechin 3-gallate ameliorates bile duct ligation induced liver injury in mice by modulation of mitochondrial oxidative stress and inflammation.

Authors:  Kezhen Shen; Xiaowen Feng; Rong Su; Haiyang Xie; Lin Zhou; Shusen Zheng
Journal:  PLoS One       Date:  2015-05-08       Impact factor: 3.240

6.  CANDIDATE GENES FOR LIMITING CHOLESTATIC INTESTINAL INJURY IDENTIFIED BY GENE EXPRESSION PROFILING.

Authors:  Samuel M Alaish; Jennifer Timmons; Alexis Smith; Marguerite S Buzza; Ebony Murphy; Aiping Zhao; Yezhou Sun; Douglas J Turner; Terez Shea-Donahue; Toni M Antalis; Alan Cross; Susan G Dorsey
Journal:  Physiol Rep       Date:  2013-09

7.  Pathophysiology of lung injury induced by common bile duct ligation in mice.

Authors:  Fumiaki Shikata; Tomohisa Sakaue; Koh-ichi Nakashiro; Mikio Okazaki; Mie Kurata; Toru Okamura; Masahiro Okura; Masahiro Ryugo; Yuki Nakamura; Takumi Yasugi; Shigeki Higashiyama; Hironori Izutani
Journal:  PLoS One       Date:  2014-04-14       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.